Galmed Pharmaceuticals Ltd (NAS:GLMD)
$ 0.3046 -0.0069 (-2.22%) Market Cap: 1.94 Mil Enterprise Value: -10.62 Mil PE Ratio: 0 PB Ratio: 0.14 GF Score: 36/100

Q4 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript

May 02, 2022 / 12:30PM GMT
Release Date Price: $18.3 (-26.51%)
Operator

Good day and welcome to the Galmed conference call to discuss financial results for the fourth quarter and year end 2021. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statement on today's call, including those regarding financial results, statements and focus regarding anticipated time lines and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events.

These statements are based on the beliefs and expectations of management as of today and actual results trends, time lines and projections relating to our financial position and projected development programs and pipeline could defer materially. We urge all investors to read carefully, the risk and uncertainties disclosed in our filings with the SEC including without limitation the risk under the heading risk factors described in our latest annual report on form 20F filed with the SEC. Galmed assumes no applications to update any forward-looking statements or information, which speak as of the respective

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot